← Russell 3000 cross-section

XNCR Xencor Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$2.1bn
Revenue TTM
$105m
Net income TTM
$-163m
Free cash flow
$-208m
Composite score
22.7
Sector rank
#1611

Valuation

P / E
EV / EBITDA
EV / sales
20.7
FCF yield
-9.85%
Earnings yield vs 10-yr
-12.46pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-155.6%
EBITDA margin
-196.2%
ROE
-32.5%
ROIC
-38.4%
Revenue growth
-33.2%

Insider activity, last 90 days

Net open-market
$-0.38m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Potential additional anti-tumor activity was observed at doses above 60 mg; however, reversible hearing impairment limited XmAb541 exposure due to the frequency of dose interruptions and dose reductions at those higher dose levels. Revenues Total revenue increased by $7.6 million for the three months ended June 30, 2026 and decreased by $20.6 million for the six months ended June 30, 2026, compared to the corresponding periods in 2025. The change was primarily driven by the revenue recognition associated with Alexion and Incyte license agreements as discussed below. …Xencor Inc, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →